

REGENERON PHARMACEUTICALS INC  
Form 4  
January 05, 2015

**FORM 4**

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Powchik Peter

(Last) (First) (Middle)

777 OLD SAW MILL RIVER ROAD

(Street)

TARRYTOWN, NY 10591

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
REGENERON  
PHARMACEUTICALS INC  
[REGN]

3. Date of Earliest Transaction (Month/Day/Year)  
12/31/2014

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_\_ Director  
 Officer (give title below) SVP Clinical Development & Reg  
\_\_\_\_ 10% Owner  
\_\_\_\_ Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)
			Code	V	Amount or Price		
Common Stock	12/31/2014		M <sup>(1)</sup>		25,000 A \$ 52.03	D	
Common Stock	12/31/2014		F <sup>(1)</sup>		3,151 D \$ 412.78	D	
Common Stock	12/31/2014		F <sup>(1)</sup>		11,027 D \$ 412.78	D	
Common Stock	01/02/2015		S <sup>(1)</sup>		1,400 D \$ 410.99	D	

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Common Stock	01/02/2015	<u>S<sup>(1)</sup></u>	1,122	D	\$ <u>(3)</u>	411.99	19,011	D	
Common Stock	01/02/2015	<u>S<sup>(1)</sup></u>	1,700	D	\$ <u>(4)</u>	412.81	17,311	D	
Common Stock	01/02/2015	<u>S<sup>(1)</sup></u>	2,758	D	\$ <u>(5)</u>	414.07	14,553	D	
Common Stock	01/02/2015	<u>S<sup>(1)</sup></u>	1,642	D	\$ <u>(6)</u>	415.2	12,911	D	
Common Stock	01/02/2015	<u>S<sup>(1)</sup></u>	900	D	\$ <u>(7)</u>	416.75	12,011	D	
Common Stock	01/02/2015	<u>S<sup>(1)</sup></u>	1,000	D	\$ <u>(8)</u>	417.44	11,011	D	
Common Stock	01/02/2015	<u>S<sup>(1)</sup></u>	300	D	\$ <u>(9)</u>	418.4	10,711	D	
Common Stock							18,000	I	by GRAT
Common Stock							1,621	I	By 401(k) Plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Security (Instr. 3 and 4)	8. Amount or Number of Shares
Non-Qualified Stock Option	\$ 52.03	12/31/2014		<u>M<sup>(1)</sup></u>	V (A) (D) 25,000	<u>(10)</u> 12/16/2021	Common Stock	25,000

(right to buy)

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Powchik Peter 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591			SVP Clinical Development & Reg	

## Signatures

/s/\*\*Peter  
Powchik

01/03/2015

\*\*Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).  
Represents volume-weighted average price of sales of 1,400 shares of Company stock on January 2, 2015 at prices ranging from \$410.48 to \$411.36. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2015 at each separate price.
- (2) Represents volume-weighted average price of sales of 1,122 shares of Company stock on January 2, 2015 at prices ranging from \$411.53 to \$412.44. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2015 at each separate price.
- (3) Represents volume-weighted average price of sales of 1,700 shares of Company stock on January 2, 2015 at prices ranging from \$412.58 to \$413.50. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2015 at each separate price.
- (4) Represents volume-weighted average price of sales of 2,758 shares of Company stock on January 2, 2015 at prices ranging from \$413.75 to \$414.56. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2015 at each separate price.
- (5) Represents volume-weighted average price of sales of 1,642 shares of Company stock on January 2, 2015 at prices ranging from \$414.97 to \$415.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2015 at each separate price.
- (6) Represents volume-weighted average price of sales of 900 shares of Company stock on January 2, 2015 at prices ranging from \$416.00 to \$416.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2015 at each separate price.
- (7) Represents volume-weighted average price of sales of 1,000 shares of Company stock on January 2, 2015 at prices ranging from \$417.03 to \$417.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2015 at each separate price.
- (8) Represents volume-weighted average price of sales of 300 shares of Company stock on January 2, 2015 at prices ranging from \$418.16 to \$418.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2015 at each separate price.
- (9) The option became exercisable with respect to all shares underlying the option on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014.
- (10)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.